<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337219</url>
  </required_header>
  <id_info>
    <org_study_id>RM/NEB-03-10</org_study_id>
    <nct_id>NCT01337219</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis</brief_title>
  <acronym>RM/NEB-03-10</acronym>
  <official_title>Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erempharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clininfo S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erempharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) is a genetic disease characterized by mutations in CFTR (Cystic Fibrosis&#xD;
      Transmembrane conductance Regulator) gene. Mortality and morbidity are mostly related to the&#xD;
      respiratory affection which appears early in neonates.&#xD;
&#xD;
      The constant improvement in symptomatic treatments and care strategies allowed CF patients'&#xD;
      life expectancy to be increased over the last decades.&#xD;
&#xD;
      Vital prognostic is related to bronchopulmonary infections. 39% of CF patients under 18 years&#xD;
      old and 70% of adult CF patients are chronically infected by Pseudomonas aeruginosa.&#xD;
&#xD;
      Elevated concentrations of tobramycin in broncho secretions, about 1000 times the MIC, is&#xD;
      obtained by inhaled administration of tobramycin and is active against in-vitro resistant&#xD;
      Pseudomonas aeruginosa.&#xD;
&#xD;
      Study hypotheses :&#xD;
&#xD;
      Regarding literature data and in-vitro studies, the administration of Nebcinal® 150mg/3ml&#xD;
      administered twice a day by Aeroneb® Idehaler® pocket® would deliver the same quantity of&#xD;
      antibiotic in lung and plasma as Tobi® 300mg/5ml administered twice a day by Pari® LC Plus®&#xD;
      in children and adult patients with CF.&#xD;
&#xD;
      Primary objective :&#xD;
&#xD;
      To compare plasma concentrations after inhalation of Nebcinal® 150mg/3ml administered by&#xD;
      Aeroneb® Idehaler pocket® and Tobi® 300 mg/5ml administered by Pari LC Plus®&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of tobramycin from 0 to 8h after administration</measure>
    <time_frame>from 0 to 8h after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sputum of tobramycin concentrations</measure>
    <time_frame>from 0 to 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®;</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of nebulization of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®</measure>
    <time_frame>during nebulization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket®</measure>
    <time_frame>after administration of the drug, in average 20 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults and children aged 6 years old and more&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Patients with cystic fibrosis (positive sudoral test, Cl &gt; 60 mmol/L)&#xD;
&#xD;
          -  Followed in a CRCM (CF care centre)&#xD;
&#xD;
          -  FEV1 ≥40%&#xD;
&#xD;
          -  Informed consent collected from adults or parents or legal guardians and children.&#xD;
&#xD;
          -  Affiliation to the National Health Insurance program (Sécurité sociale).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  renal insufficiency defined by a creatinine clearance level superior to 2 mg/dl&#xD;
&#xD;
          -  recent pneumothorax, emphysema, punction or recent pleural biopsy, recent haemoptysis&#xD;
             superior to 60 ml within 30 days prior to randomization&#xD;
&#xD;
          -  Acute pulmonary exacerbation pathology, according to conference of consensus (2002),&#xD;
             evaluated by :&#xD;
&#xD;
          -  Cough increase&#xD;
&#xD;
          -  Sputum increase&#xD;
&#xD;
          -  Decrease in tolerance to effort&#xD;
&#xD;
          -  Loss of weight, lack of appetite&#xD;
&#xD;
          -  Deterioration of respiratory function&#xD;
&#xD;
          -  Medical history of intolerance, toxicity or allergy to tobramycin, hypersensitivity to&#xD;
             aminoside&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Bellon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Resources et de competences pour la mucovisidose</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Durieu, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Resources et de competences pour la mucovisidose Hôpital Lyon Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>behrouz Kassai, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University of Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Behrouz Kassaï</last_name>
    <phone>04 27857732</phone>
    <phone_ext>0033</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Paul Salin</last_name>
    <phone>0140899260</phone>
    <phone_ext>0033</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Bellon, Pr</last_name>
      <phone>04 27 85 59 82</phone>
      <phone_ext>0033</phone_ext>
      <email>gabriel.bellon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel Bellon, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Erempharma</name_title>
    <organization>Erempharma</organization>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>sputum</keyword>
  <keyword>plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

